Immunotherapy of melanoma

Bennett, 1899, Lancet, 1, 3

Jakob, 2012, NRAS mutation status is an independent prognostic factor in metastatic melanoma, Cancer, 118, 4014, 10.1002/cncr.26724

Kalialis, 2009, Spontaneous regression of metastases from melanoma: review of the literature, Melanoma Res, 19, 275, 10.1097/CMR.0b013e32832eabd5

Oble, 2009, Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma, Cancer Immun, 9, 3

Clemente, 1996, Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, Cancer, 77, 1303, 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5

Erdag, 2012, Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma, Cancer Res, 72, 1070, 10.1158/0008-5472.CAN-11-3218

Bakker, 1994, Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes, J Exp Med, 179, 1005, 10.1084/jem.179.3.1005

Brichard, 1993, The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas, J Exp Med, 178, 489, 10.1084/jem.178.2.489

Castelli, 1995, Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes, J Exp Med, 181, 363, 10.1084/jem.181.1.363

Gaugler, 1994, Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes, J Exp Med, 179, 921, 10.1084/jem.179.3.921

Huang, 1999, Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma, J Immunol, 162, 6849, 10.4049/jimmunol.162.11.6849

Jager, 1998, Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes, J Exp Med, 187, 265, 10.1084/jem.187.2.265

Kawakami, 1994, Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor, Proc Natl Acad Sci U S A, 91, 3515, 10.1073/pnas.91.9.3515

Kvistborg, 2012, TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients, Oncoimmunology, 1, 409, 10.4161/onci.18851

Romero, 1997, Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma, J Immunol, 159, 2366, 10.4049/jimmunol.159.5.2366

Traversari, 1992, A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E, J Exp Med, 176, 1453, 10.1084/jem.176.5.1453

Hodis, 2012, A landscape of driver mutations in melanoma, Cell, 150, 251, 10.1016/j.cell.2012.06.024

Krauthammer, 2012, Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma, Nat Genet, 44, 1006, 10.1038/ng.2359

Rosenberg, 1998, Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response, Ann Surg, 228, 307, 10.1097/00000658-199809000-00004

Kammula, 1998, Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer, Cancer, 83, 797, 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M

Atkins, 1999, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993, J Clin Oncol, 17, 2105, 10.1200/JCO.1999.17.7.2105

Morgan, 1976, Selective in vitro growth of T lymphocytes from normal human bone marrows, Science, 193, 1007, 10.1126/science.181845

Joseph, 2012, Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma, J Immunother, 35, 66, 10.1097/CJI.0b013e3182372636

Weiss, 2011, Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma, Clin Cancer Res, 17, 7440, 10.1158/1078-0432.CCR-11-1650

Lee, 1998, Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy, Cancer J Sci Am, 4, 86

Rosenberg, 1989, Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients, Ann Surg, 210, 474, 10.1097/00000658-198910000-00008

Schwartzentruber, 2011, Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma, N Engl J Med, 364, 2119, 10.1056/NEJMoa1012863

Seung, 2012, Phase 1 study of stereotactic body radiotherapy and interleukin-2 – tumor and immunological responses, Sci Transl Med, 4, 137ra74, 10.1126/scitranslmed.3003649

Maker, 2005, Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study, Ann Surg Oncol, 12, 1005, 10.1245/ASO.2005.03.536

Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514

Brunet, 1987, A new member of the immunoglobulin superfamily – CTLA-4, Nature, 328, 267, 10.1038/328267a0

Pentcheva-Hoang, 2004, B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse, Immunity, 21, 401, 10.1016/j.immuni.2004.06.017

Peggs, 2008, Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy, Immunol Rev, 224, 141, 10.1111/j.1600-065X.2008.00649.x

Waterhouse, 1995, Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4, Science, 270, 985, 10.1126/science.270.5238.985

Grosso, 2013, CTLA-4 blockade in tumor models: an overview of preclinical and translational research, Cancer Immun, 13, 5

van Elsas, 1999, J Exp Med, 190, 355, 10.1084/jem.190.3.355

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239

Phan, 2003, Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, Proc Natl Acad Sci U S A, 100, 8372, 10.1073/pnas.1533209100

Ribas, 2005, Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206, J Clin Oncol, 23, 8968, 10.1200/JCO.2005.01.109

Weber, 2009, A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma, Clin Cancer Res, 15, 5591, 10.1158/1078-0432.CCR-09-1024

Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466

Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 2517, 10.1056/NEJMoa1104621

Ribas, 2012, Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion, J Transl Med, 10, 236, 10.1186/1479-5876-10-236

Ribas, 2013, Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, J Clin Oncol, 31, 616, 10.1200/JCO.2012.44.6112

Voskens, 2013, The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network, PLoS One, 8, e53745, 10.1371/journal.pone.0053745

Wilgenhof, 2011, Anti-CTLA-4 antibody-induced Guillain–Barre syndrome in a melanoma patient, Ann Oncol, 22, 991, 10.1093/annonc/mdr028

Vogel, 2012, Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission, J Clin Oncol, 30, e7, 10.1200/JCO.2011.37.9693

Callahan, 2010, Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy, Semin Oncol, 37, 473, 10.1053/j.seminoncol.2010.09.001

Delyon, 2013, Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival, Ann Oncol, 24, 1697, 10.1093/annonc/mdt027

Nishimura, 2001, PD-1: an inhibitory immunoreceptor involved in peripheral tolerance, Trends Immunol, 22, 265, 10.1016/S1471-4906(01)01888-9

Chemnitz, 2004, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation, J Immunol, 173, 945, 10.4049/jimmunol.173.2.945

Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat Immunol, 2, 261, 10.1038/85330

Blank, 2005, Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy, Cancer Immunol Immunother, 54, 307, 10.1007/s00262-004-0593-x

Dong, 2002, Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm730

Taube, 2012, Colocalization of inflammatory response with B7–h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape, Sci Transl Med, 4, 127ra37, 10.1126/scitranslmed.3003689

Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J Clin Oncol, 28, 3167, 10.1200/JCO.2009.26.7609

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694

Rosenberg, 1993, Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer, J Natl Cancer Inst, 85, 622, 10.1093/jnci/85.8.622

Dudley, 2005, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma, J Clin Oncol, 23, 2346, 10.1200/JCO.2005.00.240

Gattinoni, 2005, Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells, J Exp Med, 202, 907, 10.1084/jem.20050732

Dudley, 2008, Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens, J Clin Oncol, 26, 5233, 10.1200/JCO.2008.16.5449

Dudley, 2010, CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma, Clin Cancer Res, 16, 6122, 10.1158/1078-0432.CCR-10-1297

Besser, 2010, Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients, Clin Cancer Res, 16, 2646, 10.1158/1078-0432.CCR-10-0041

Joseph, 2011, Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy, Clin Cancer Res, 17, 4882, 10.1158/1078-0432.CCR-10-2769

Pilon-Thomas, 2012, Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma, J Immunother, 35, 615, 10.1097/CJI.0b013e31826e8f5f

Schumacher, 2002, T-cell-receptor gene therapy, Nat Rev Immunol, 2, 512, 10.1038/nri841

Gross, 1989, Expression of immunoglobulin–T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc Natl Acad Sci U S A, 86, 10024, 10.1073/pnas.86.24.10024

Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540

Grupp, 2013, Chimeric antigen receptor-modified t cells for acute lymphoid leukemia, N Engl J Med, 10.1056/NEJMoa1215134

Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849

Johnson, 2009, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, 114, 535, 10.1182/blood-2009-03-211714

Morgan, 2013, Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy, J Immunother, 36, 133, 10.1097/CJI.0b013e3182829903

Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003

Robbins, 2011, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1, J Clin Oncol, 29, 917, 10.1200/JCO.2010.32.2537